Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 185 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide 2 MG, Dapagliflozin 10 MG
Drug
Lead sponsor
Consano Clinical Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Shavano Park, Texas
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Conditions
Hyperglycemia, Acute Coronary Syndromes, Myocardial Infarction
Interventions
Exenatide
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Exenatide, Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Kansas City, Kansas • Baltimore, Maryland • New York, New York
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Renton, Washington
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
126
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

NCT03167411
Conditions
Type2 Diabetes Mellitus
Interventions
Bexagliflozin, Exenatide Injection
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Type 2 Diabetes
Interventions
Placebo, Exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Results available

Intravenous Exenatide (Byetta) During Surgery

NCT00882050
Conditions
Euglycemia, Hypoglycemia, Hyperglycemia
Interventions
Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions
extended-release exenatide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetes Mellitus, Type 2
Interventions
ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin, Liraglutide
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Little Rock, Arkansas + 28 more
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

Exenatide for Treating Cocaine Use Disorder

NCT04941521
Conditions
Cocaine Use Disorder
Interventions
Exenatide 2 mg [Bydureon], Drug Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Type 2 Diabetes
Interventions
Exenatide, Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetes Mellitus
Interventions
Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

Impact of Exenatide on Sleep in Type 2 Diabetes

NCT01136798
Conditions
Type 2 Diabetes, Sleep Disordered Breathing
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Chicago, Illinois